Boehringer Ingelheim

News

Boehringer drug scores in another pulmonary fibrosis trial

Boehringer Ingelheim has a second positive trial under its belt for nerandomilast in pulmonary fibrosis, setting up regulatory filings.

News

Boehringer drug for brain fog in schizophrenia fails trial

Boehringer Ingelheim's bid to develop the first drug therapy for impaired cognitive function in schizophrenia looks like it has reached an end.

Sales & Marketing

Veeva Summit - Chris Moore, president of Veeva Europe

A next-generation mindset: Veeva Commercial Summit 2024

Imagine a time when all your teams collaborate seamlessly. That’s what this year’s Veeva Commercial Summit posited as it commenced.

Patients

hands holding paper head representing protecting the mind

Keeping stigma out of it: Personalising the mental health co...

Thursday 10th October was World Mental Health Day, focused this year on ‘mental health at work’.

News

Ono, Boehringer add to cancer pipelines with licensing deals

Ono Pharma and Boehringer Ingelheim both added to their cancer pipelines, licensing drugs from LigaChem Bio and Circle Pharma, respectively.

R&D